2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
生物活性
Description
In Vivo
In Vitro
化合物的使用
Kinase Assay
Cell Assay
Animal Administration
参考文献
SB 202190 is a pyridinyl imidazole that inhibits the p38 pathway. The compound inhibits the iso Forms p38α and p38β. SB 202190 has displayed the ability to activate CPP32-like caspases and induce apoptosis. Research demonstrates that when one residue of ERK2, a related p38 not inhibited by pyridinyl imidazoles, is changed it allows SB 202190 to bind. Studies have revealed that SB 202190 can improve leukemia cell growth by activating MEK/MAPK, as well as phosphorylate and activate MLK3.
For the detailed information about the solubility of SB 202190 (FHPI) in water, the solubility of SB 202190 (FHPI) in DMSO, the solubility of SB 202190 (FHPI) in PBS buffer, the animal experiment（test） of SB 202190 (FHPI), the in vivo,in vitro and clinical trial test of SB 202190 (FHPI), the cell experiment（test） of SB 202190 (FHPI), the IC50, EC50 and Affinity of SB 202190 (FHPI) , please contact DC Chemicals.
